Close Menu

NEW YORK – OpGen said after the close of the market on Friday that it received a notice from Nasdaq that as of June 30 the company does not comply with a listing requirement calling for a minimum shareholder equity of $2.5 million.

As a result, the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology could face delisting action by Nasdaq. OpGen has 45 calendar days to submit a plan to regain compliance. If Nasdaq accepts the plan, it can grant the company an extension of up to 180 calendar days to become compliant with the listing requirement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.